Stocks Listing
AZN

AstraZeneca PLC

Share
AZN
$55.55 1.29%Last Updated Oct 03 2022 08:16 PM
1D Low / 1D High
Low:$54.83
High:$55.66
1D
1.29%
5D
4.34 %
30D
8.47 %
BulletPurple
Market Cap
$168,889,778,176
1.29 %
168.9 B
BulletBlue
Volume 1D
6,065,865
-
6.1 M
BulletOrange
Circulating Supply
3,040,320,039 AZN
3 B

Price Chart

1D
5D
1M
6M
YTD
1Y
MAX
About

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; Proteros biostructures GmbH to discover and develop novel small molecules. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; and Scorpion Therapeutics, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. The company was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Read More

Historical data

1D
5D
1M
6M
1Y
MAX
Day
Open - Close
Low/High
Volume
Market Cap
Show More
Reddit
Market Status
Closed
NMS
NASDAQ Stock Exchange
USA
Opens in
16 hours, 0 minutes
Working Hours
Mon-Fri, 01:30 PM - 08:00 PM
Timezone
GMT+0